roche molecular medicine laboratories biomarkers in personalized health care: opportunities,...
Post on 27-Mar-2015
213 Views
Preview:
TRANSCRIPT
Roche Molecular Medicine Laboratories
Biomarkers in Personalized Health Care: Opportunities, Challenges, ApproachesKlaus Lindpaintner
Roche Molecular Medicine Laboratories
Case Report 1: Ms. Silvia R., 28
• Started on imipramine 25 mg tid
• No improvement 3 weeks later
• Dose increased to 50 mg tid
• No improvement 3 weeks later
• Switched to paroxetine 20 mg qd
• No improvement 3 weeks later
• One week later admitted to hospital in critical condition after attempted suicide
Depression
• Patient w/ pneumonia treated w/ antibiotics and w/ codeine for cough
• On treatment day 4 patient was found unresponsive
• Transfer into ICU, life support: intubation, respirator
• Supportive care was successful – patient recovered fully
Case report 2: Joon C., MD, 34Pneumonia
1997 Diagnosis: breast cancer Prognosis: 3 years to live
On her 55. birthday…
On January 12, 2006
Case Report 3: Ms. Regula SBreast Cancer
Case Report 4: Patient #45
Day 15Baseline
Metastatic malignant melanoma
Proper treatments – improper dose
• Gene test for CYP450-2D6, indicates ultra-rapid variant in both patients
• Resulting in
• Ineffective dose in case 1
• Effective overdose in case 2
Drug metabolism Inherited differences affect drug effects
Pro-drug activation Same principle – turned on its head
Ineffective
Adverse events
nl HER2
HER2
Personalized Approach to the patientExample: breast cancer, Herceptin®
Breast cancer facts: 700,000 new cases in Europe and the US -- 200,000 deaths One in 10 women will contract breast cancer in her life-time
Breast cancer facts, updated: 2/3 of all patients: 7 years survival 1/3 of all patients: 3 years survival
growth factor Her2 - growth factor Her2 +
Diagnosis for Ms Regula S.:
(1) Biopsy: + (2) HerCep-Test: + Herceptin® therapy initiated
BRAF KinaseAn Important Mediator of Cellular Proliferation
MembraneRTK
Y-PY-P Ras GTP
Other Effectors
Growth Factors
RAF
MEK
ERK
P
P
Nuclear TranslocationGene Expression
BRAFV600E
MEK
ERK
P
P
Abnormal CellularProliferation
Normal signaling
Oncogenic signaling
Arrested
Personalized health careTwo fundamentally different concepts, one consequence• Genetic Concept – Archibald Garrod, (sulphonal-induced
porphyria)– Molecular variant is immaterial to disease– Inherited susceptibilities to xenobiotics (drugs, nutrients)– Generally affects pharmacokinetics– Static– Example; CyP450, UGT
• Molecular Concept – Disease Cause-Effect Targeting– Molecular variant fundamentally important to disease pathology– “rewriting the textbook of medicine” based on molecular
understanding– Generally affects pharmacodynamics, causation-driven treatments– Dynamic– Example: Her2, BRAF
Case Report 5: State of the PharmacopoeiaA call for more effective and safer drugs
1 Spears et al., Trends Mol Med, 2001; 2 Lazarou et al., JAMA, 1998
Drug Response Rate, %
An
alg
esic
s
0
20
40
60
80
Can
cer
Efficacy Safety
Case Report 6: NME track recordStep-change needed in pharmaceuticals development
Sources: FDA/CDER Data, PhRMA data, Price Waterhouse Coopers analysis, Pharma 2020
R&D spend
New Molecular Entities (NME)$ 47 bn
$ 17 bn 17
53
1996 2007
Case report 7: New technologiesExpanding our understanding of diseases
IHC/ISH
BenchmarkMicroarrayanalysis
AmpliChip Sequencing
Real-time PCR
TaqMan
Multiplexproteins
Impact
Elecsys
ELISA
Healthcare Pressures:
Benefit-Risk Ratio
Economic Pressures:
Benefit-Cost Ratio
New Technologies:
Expanded Capabilities
Need for highly differentiated medicinesthat have a clear impact on individual and public health
Only truly innovative medicines will find acceptance
Innovative ~ Personalized
PHC as Key Driver of Change Key to enabling highly differentiated medicines
Messages: Personalized Healthcare
• Essential to progress in individual patient care
• Conceptually nothing new
• Requires thoughtful, differentiated consideration:Context and Information Content
Personalized Healthcare
•General considerations
•Qualification and Utility of Biomarkers
•Study Design Considerations
•Economical and Ethical Considerations
Opportunities & Challenges
Personalized Healthcare
•General considerations
•Qualification and Utility of Biomarkers
•Study Design Considerations
•Economical and Ethical Considerations
Opportunities & Challenges
Personalized Health CareA definition
Discovery and development of pharmaceuticals and diagnostics that better account for human variation and for the diverse molecular basis of disease.
Use of biomarkers expected to be critical to facilitate this differentiation.
Personalized Medicine, Biomarkers Pharmacogenetics:An altogether new concept??
• Finding the optimal treatment for every patient is as old as medicine: differential diagnosis
• 530 BC: Pythagoras observes that some peopletolerate the ingestion of fava-beans, others not
1960 AD: glucose-6-phosphate-dehydrogenase deficiency recognized as the cause
1990 AD: SNPs in the G6PD gene characterized
• Tailoring treatments to drug-specific test results is nothing new. Example: antibiotics
– Gram-positive bacteria: e.g. penicillin derivatives– Gram-negative bacteria: e.g. aminoglycosides– M. tuberculosis: isoniazid/rifampin/pyrazinamide
Biomarkers and Personalized Health CareWhat is new – and why now?
• Since~1980: Availability of powerful, highly parallel new screening methods (omics) makes hypothesis-free search for new biomarkers and for new treatment approaches a reasonable proposition.
• Since ~2000: Paradigm shift(?): maturation of these basic cell and molecular biology tools makes them newly applicable to later-stage R&D and clinical practice as robust, reliable diagnostics
Translation of extant, older as well as newly emerging knowledge into clinical practice
Complexity of ScienceA biomarker might be more difficult to find than a drug
Biomarker = Any biological parameter used as indicator of disease process or drug response
Potentially valuable
Early stage assessment
1
10’s
100’s
1000’s biomarkers
Clinical use
Exploratory
Biomarker Development – RequirementsSignificant hurdles
Generation of a biomarker hypothesis
Develop prototype assay
Identification of candidate markers
Discovery Clinical validation of candidate markers using assay
Assay refinement & development IVD test
Regulatory test approval
Validation Distribution to laboratories
Auditing for result consistency
CommercialisationClinician/Lab education
Confirmatory Phase
Dx launch/ Post-launch assessment
Biomarker development
Making PHC happenA complex undertaking
Target Selectio
n
Exploratory PhaseDiscove
ryPhase
Research
Companion diagnosticfeasibility & attractiveness
Tailored prescribing & monitoring
Target identification
Patient selection
Research assay Technically validated assayClinically validated IVD assay
Develop CommercialiseLead
Generation/
Optimisation
Phase 0 Phase I Phase II Phase III FilingMarket
Phase IV
PoC
Personalized Healthcare
•General considerations
•Qualification and Utility of Biomarkers
•Study Design Considerations
•Economical and Ethical Considerations
Opportunities & Challenges
“Responders”, “Non-Responders” Reality Check
0
10
20
30
40
50
60
70
80
resp
on
se (
%)
individual patients
31%
0
10
20
30
40
50
60
70
80
resp
on
se (
%)
individual patients
43%
22%
Regulatory agency benchmark: 35% improvement/response (hypothetical)
AN
Biomarker test performance, qualificationDiverse considerations
• Analytical performance: QC and accreditation of labs
• Clinical validity: retrospective/observation studies
• Clinical utility: prospective intervention trials
• Note: Prior probability (i.e. context): critical for test performance (i.e. information content), esp. screens (sensitivity/specificity, PPV/NPV)
Biomarker test performance, qualificationDiverse considerations
• Analytical performance: QC and accreditation of labs
• Clinical validity: retrospective/observation studies
• Clinical utility: prospective intervention trials
• Note: Prior probability (i.e. context): critical for test performance (i.e. information content), esp. screens (sensitivity/specificity, PPV/NPV)
Analytical performance… not a foregone conclusion
Biomarker test performance, qualificationDiverse considerations
• Analytical performance: QC and accreditation of labs
• Clinical validity: retrospective/observation studies
• Clinical utility: prospective intervention trials
• Note: Prior probability (i.e. context): critical for test performance (i.e. information content), esp. screens (sensitivity/specificity, PPV/NPV)
Study DesignJustifying the (implicit) conclusions?
Patients and MethodsChemotherapy-naive patients with advanced NSCLC with 1 clinical characteristic associatedwith EGFR mutations underwent direct DNA sequencing of tumor tissue EGFR exons 18 to 21. Patients found to harbor any EGFR mutation were treated with gefitinib 250 mg/d until progression or unacceptable toxicity. The primary outcome was response rate.ConclusionsFirst-line therapy with gefitinib administered in a genotype-directed fashion to patients with advanced NSCLC harboring EGFR mutations results in very favorable clinical outcomes with good tolerance. This strategy should be compared with combination chemotherapy, the current standard of care.
Biomarker test performance, qualificationDiverse considerations
• Analytical performance: QC and accreditation of labs
• Clinical validity: Proper study design essential retrospective/observation studies
• Clinical utility: prospective intervention trials
• Note: Prior probability (i.e. context): critical for test performance (i.e. information content), esp. screens (sensitivity/specificity, PPV/NPV)
labeled DNA target
Oligonucleotide probe
** **
*
The Roche CYP450 AmplichipPioneering technology and the challenge of clinical utility• Broad allelic coverage of known
variants, for many ethnic groups(CYP2D6 and CYP2C19)
• Introduced micro-array technology to diagnostics
• CE, FDA Certified – first-in-class device
• Analytical Performance (new gold standard) Clinical Validity Clinical Utility (psychiatry, CVD): t. b. d.
Ultimately: need to demonstrate incremental cost-effectiveness ratio acceptable to payers a new era of “ph III studies” in Dx
Context: Tamoxifen and CYP450 2D6Testing prior to treatment?
N-desmethyl-tamoxifen (NDM)
Tamoxifen
CYP3A4/5
4-hydroxy-N-desmethyl-tamoxifen (endoxifen) CYP2D6
Personalized Healthcare
•General considerations
•Qualification and Utility of Biomarkers
•Study Design Considerations
•Economical and Ethical Considerations
Opportunities & Challenges
Study Design Considerations (1) Context: Nature of illness, aim of marker“Biomarker Target Product Profile: First, do no
harm!”
• Serious (life-threatening) illnessDefault: ”don’t withhold in error”; If in doubt: “treat”
• Less serious illnessDefault: “don’t treat in error”; If in doubt: “don’t treat”
Biomarker Target Product Profile
Efficacy marker: High sensitivity
Safety marker: High specificity
Efficacy marker: High specificity
Safety marker: High sensitivity
Less serious illness: don’t prescribe inappropriately
Serious illness: don’t withhold inappropriately
Determined by Context and Information Content
Study Design Considerations (2)
• 2 fundamentally different Objectives– Advancing fundamental understanding, but clinically not
necessarily actionable “p-value”-driven
– Finding clinically actionable biomarkers: information content in given context! “magnitude-of-effect”-driven; p essential but not sufficient
• Indication• Efficacy vs. Safety• Phase of trial
• Effects on Study Design:– Type of specimens – Number of specimens
Defining the Target Product Profile – Controlling Costs – Debunking Myths
Lost in Translation
OR = 1.5
OR =1.15
OR = 9
sens/spec = 55%
sens/spec = 51%
sens/spec = 75%
Different scientific terminologies in research and clinic
Lost in Translation
Posit: significance 0.05, power 85%
Different scientific terminologies in research and clinic
Lost in Translation
n = 936
n = 7456
n = 42
Different scientific terminologies in research and clinic Consequences:
OR = 1.5
OR =1.15
OR = 9
sens/spec = 55%
sens/spec = 51%
sens/spec = 75%
Personalized Healthcare
•General considerations
•Qualification and Utility of Biomarkers
•Study Design Considerations
•Economical and Ethical Considerations
Opportunities & Challenges
Personalized Medicine – Challenges
• Economic
“Exhaustive pharmacogenetic research efforts have narrowed your niche market down
to Harry Finkelstein of Newburg Heights here.”
Economics of stratification drive PHC Creating patient benefits and commercial incentives
Unstratified Medicine
Stratified Medicine
Reduced
Eligible
Patient
Population
Patient benefit:
• Optimal efficacy
• Avoid unnecessary treatment / side effects
• Decreased uncertainty
•Penetration
•Market share
•Duration of therapy
•Adherence
•Line extensions
Economics of stratification drive PHC Creating patient benefits and commercial incentives
Unstratified Medicine
Stratified Medicine
Reduced
Eligible
Patient
Population
Payer Acceptance
The Tightening Reimbursement ClimateBiomarker strategies may be essential
Strategy Incr. Cost UK £
Incr Cost/QUALY
UK £ No test Chemo-Rx alone
26,919 21,030
Positive HerCep Test Chemo-Rx and Herceptin
33,376 24,541
No test Chemo-Rx and Herceptin
49,211 35,920
Elkin et al; J Clin Oncol 2004; 22:854 ff
($/£ conv. rate 1/1/2003, not PPP-adjusted)
NB: National Institute for Clinical Excellence’s (NICE) threshold for approving reimbursement through NHS believed to be ~UK £ 30,000 per QUALY (quality-adjusted life year)
Biomarker AdoptionEvidence counts
Results: In the base case, genotype-guided dosing resulted in better
outcomes, but at a relatively high cost. Overall, the marginal
cost-effectiveness of testing exceeded $170 000 per QALY…
A friendly nudge…
Ethical, Legal, Societal ConsiderationsDo we need to reinvent the wheel?•Autonomy: privacy and respect
•Confidentiality– Patient protection more important
than data protection – GINA – Information content, not type counts:
counter “genetic exceptionalism”
•Beneficence: do good
•No Maleficence: don’t do harm
Biomarkers - Personalized MedicineSummary
• Conceptually nothing new – nothing to be afraid of!
• Essential to progress in individual patient care– Only more differentiated understanding of patients/disease will allow
progress in health care
• Requires thoughtful, differentiated consideration– Avoid black-and-white thinking:
complex disease pathology is complex – context counts– High demand on information-content of test:
Evidence-based implementation– Essential: create win-win scenarios with payers– Not a panacea: we will not always find a biomarker,
but we must always try.
• Motto: Robust (aggressive?) optimism – paired w/ realism and modesty!
No 1-on-1 custom tailoring, but towards a much better fit …
38 4039 39½ 373/4
Remember: All medical decisions/knowledge are based on group-derived (aggregate) data analysis – “individual”data are anecdotal and cannot be validated.
We Innovate Healthcare
top related